"Nexus Copy Number was designed from the ground-up with the aim of getting the scientist back in the driver's seat in analyzing their data and making rapid discoveries." said Dr. Soheil Shams, President of BioDiscovery. "We are extremely pleased with the market reception we have seen to our paradigm shifting design having most of the top copy number research labs across the globe adopt Nexus Copy Number as their primary tool for analysis of large scale data. Our customers are enthusiastic about the power Nexus Copy Number provides in an intuitive fashion allowing them to accelerate their research many folds".
"We have been using Nexus for the past six months to explore chromosomal loss data in glioblastomas and meningiomas. My lab members have found the tools and visualizations now possible in Nexus Copy Number to greatly accelerate their exploration of the datasets and drill down to interesting individual genes and gain insights that were quite difficult previously." said Dr. Stanley Nelson, Director, UCLA Site of the NIH Neuroscience Microarray Consortium. "We are excited about the new release which expands and builds on the Nexus platform for greater flexibility and more powerful analyses. Thanks for creating a very useful product!"
Dr. Hai Yan, Assistant Professor at Duke University Medical Center says "Nexus makes my life and my student's life so easy. It has so many features which allow us to analyze the data and output them in the ways we want. I give it five stars!"
Striving to provide a complete analysis package to the copy number researcher, BioDiscovery has introduced the ability to integrate external gene expression and miRNA results to any copy number analysis project allowing the scientist to rapidly overlay this data on chromosomal aberrations regions. Visualization of such integrated data is augmented with unique advanced statistical methods enabling the researcher to identify areas of genomic "hotspots" having a concordance of multiple events in a small area. Using a novel BioDiscovery invented approach in Nexus Copy Number Professional version 3.0, researchers can also identify biological functions affected by chromosomal aberrations without specifying any a priori cut-offs. Other new features in version 3.0 include many enhancements to the existing novel clustering scheme including the ability to view clinical annotations on the dendrogram branches and factor enrichment which allows the user to quickly identify clinical factors that are enriched in a particular cluster.
About BioDiscovery, Inc. BioDiscovery is a leader in the development of microarray advanced bioinformatics software and services that enable its customers to revolutionize drug discovery and diagnostics by efficiently managing, integrating, and analyzing data generated using high-throughput microarray technology. Contact BioDiscovery: 310-414-8100 or www.biodiscovery.com
